Endogenous Competition of circ_001024 for miR-145-3p in RCC

Overview

This study identifies Circ_001024 as significantly upregulated in renal cell carcinoma (RCC) tissues, correlating with disease advancement. It explores the role of Circ_001024 in RCC progression and its potential as a therapeutic target.

Background

Renal cell carcinoma (RCC) is a prevalent malignancy with a high risk of recurrence and metastasis post-surgery. Understanding the molecular mechanisms underlying RCC is crucial for developing personalized treatment strategies. Circular RNAs (circRNAs) like Circ_001024 may play a significant role in RCC pathogenesis by interacting with microRNAs.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• Circ_001024 is significantly upregulated in RCC tissues.
• Its expression correlates with disease advancement in RCC patients.
• CircRNAs can function as microRNA sponges, influencing cancer progression.
• Understanding circRNA interactions may provide insights into RCC treatment strategies.
• Further investigation is needed to explore the regulatory network of circRNAs in RCC.

Clinical Implications

The identification of Circ_001024 as a potential biomarker for RCC progression may aid in early diagnosis and personalized treatment approaches. Targeting circRNA interactions could represent a novel therapeutic strategy in managing RCC.

Conclusion

Circ_001024's role in RCC highlights the importance of circRNAs in cancer biology and their potential as therapeutic targets. Further research is essential to fully elucidate their mechanisms in RCC.

Related Resources & Content

1. Gastric Cancer, 2019 -- CircDUSP16 facilitates gastric cancer progression and invasion through miR-145-5p sponging
2. Journal of Gastroenterology, 2025 -- The Critical Function of SFRP2 in Enhancing Glycolysis and Disease Advancement in High-Risk Colorectal Cancer Patients Based on a Glycometabolism Prognostic Model
3. Archives of Toxicology, 2021 -- Influence of microRNAs on the response to cadmium chloride in pancreatic ductal adenocarcinoma
4. The Journal of Clinical Endocrinology & Metabolism -- Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia
5. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2024
6. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
7. Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition
8. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
9. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial - PubMed
10. Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition - The ASCO Post